Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

At the J.P. Morgan Healthcare Conference, Boston Scientific forecast that pulsed field ablation will be used in more than 60% of atrial fibrillation procedures globally by 2026.

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins. See ...

PFA treats atrial fibrillation by targeting heart tissue with nonthermal electrical energy, compared with the heat used in radiofrequency ablation (RFA) and the extreme cold of cryoablation. Medtronic ...

Unlike conventional radiofrequency ablation and cryoablation for atrial fibrillation ... the first PFA system to receive FDA approval, Medtronic's PulseSelect PFA system, which has been approved ...

First-in-human studies are scheduled for 2021.46 47 Radiofrequency ablation (RFA) with the Barrx device (Medtronic, Dublin ... available data for use in the oesophagus are still limited. Cryoablation ...

Medtronic is a solid dividend-paying stock. Its stock recently yielded 3.2%. It has increased its payout for nearly 50 years in a row. If you're a dividend investor, I can understand why ...